Venus Remedies share price
You have to be logged in to add this to Watchlist.- ₹336.80(8.09%)April 17, 2025 15:59:48 PM IST
- NSE
- BSE
- Vol : 283.27K (NSE + BSE)Last 20 day avg : 70.50 K
Venus Remedies is trading 8.09% upper at Rs 336.80 as compared to its last closing price. Venus Remedies has been trading in the price range of 354.00 & 311.90. Venus Remedies has given 6.33% in this year & 12.45% in the last 5 days. Venus Remedies has TTM P/E ratio 12.21 as compared to the sector P/E of 29.14.The company posted a net profit of 19.60 Crores in its last quarter.Listed peers of Venus Remedies include Albert David (1.40%), Medico Remedies (-%), Venus Remedies (8.09%).The Mutual Fund holding in Venus Remedies was at -% in . The MF holding has - from the last quarter. The FII holding in Venus Remedies was at 1.11% in 31 Dec 2024. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Apr 19, 2025, 04:59 PM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BIn line with historical values0.93The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values12.98Price-to-earnings ratio based on trailing 12-month earnings
- BetaHigh volatility1.35Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.08The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in December quarter by 23.32% from Rs 176.86 crore to Rs 143.42 crore, year-on-year
- The company has grown its December quarter profit by 186.13% from Rs 6.85 crore to Rs 19.60 crore, year-on-year
The debt to equity of the company is higher than the industry median
- R1
- 340.47
- R2
- 381.33
- R3
- 408.67
- S1
- 272.27
- S2
- 244.93
- S3
- 204.07
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Albert David | Neutral | 857.55 | 1.40 | 489.42 | 6.41 | 1.27 | 1.35 | 0.16 |
| Medico Remedies | - | 56.74 | - | 470.85 | 56.97 | 9.02 | - | 1.66 |
| Venus Remedies | Bullish | 336.80 | 8.09 | 450.20 | 15.89 | 0.93 | - | 7.93 |
| Zim Laboratories | Neutral | 89.40 | -2.03 | 435.61 | 25.20 | 1.82 | - | 16.15 |
| Sms Lifesciences India | Bullish | 1,479.00 | 16.23 | 447.14 | 47.72 | 2.45 | 0.10 | 20.10 |
- Promoter(s) holding is moderate at 41.76%
- FIIs are invested in this company
- FIIs holding has decreased by 0.07 percentage points from previous quarter
- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-02-04 | Quarterly Results |
| 2024-10-29 | Quarterly Results |
| 2024-08-13 | Quarterly Results & A.G.M. |
| 2024-07-20 | Others |
| 2024-05-30 | Audited Results |
- IndustryBiotechnology & Drugs
- ISININE411B01019
- BSE Code526953
- NSE CodeVENUSREM
Venus Remedies is trading at 336.80 as on Thu Apr 17 2025 10:29:48. This is 8.09% upper as compared to its previous closing price of 311.60.
The market capitalization of Venus Remedies is 450.20 Cr as on Thu Apr 17 2025 10:29:48.
The 52 wk high for Venus Remedies is 427.30 whereas the 52 wk low is 272.20
Venus Remedies can be analyzed on the following key metrics -
- TTM P/E: 12.21
- Sector P/E: 29.14
- Dividend Yield: 0.00%
- D/E ratio: -
Venus Remedies reported a net profit of 28.49 Cr in 2024.